Kelly and Chiu were two research scientists at Amersham International, subsequently taken over by GE Healthcare. They were involved with the first synthesis of a compound called P53, which later formed the basis of a patented radioactive imaging agent which was a highly successful product ("Myoview") for their employers - the drug netted £1.3 billion in revenues up to 2007 and completely transformed Amersham's commercial standing.